Best Medical Stocks To Consider – November 5th

Stryker, Gilead Sciences, McKesson, Medtronic, and Boston Scientific are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare, such as pharmaceutical and biotechnology firms, medical-device makers, and healthcare providers. Investors may consider them for exposure to healthcare demand and innovation, though their performance can be affected by factors such as regulation, clinical-trial results, and patent expirations. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Stryker (SYK)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Shares of SYK stock traded down $7.10 during midday trading on Thursday, hitting $332.55. 2,208,091 shares of the company were exchanged, compared to its average volume of 2,497,178. Stryker has a 52 week low of $267.00 and a 52 week high of $389.33. The firm has a market capitalization of $126.60 billion, a P/E ratio of 35.38, a PEG ratio of 2.13 and a beta of 0.78. The firm’s 50 day moving average price is $292.21 and its two-hundred day moving average price is $323.91. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 2.18.

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Gilead Sciences stock traded down $3.84 during trading hours on Thursday, hitting $170.64. The company had a trading volume of 4,221,102 shares, compared to its average volume of 6,826,180. The firm has a 50-day moving average of $152.29 and a 200 day moving average of $140.52. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. The firm has a market cap of $211.65 billion, a PE ratio of -54.00 and a beta of 0.35. Gilead Sciences has a one year low of $116.88 and a one year high of $176.58.

McKesson (MCK)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Shares of NYSE:MCK traded up $23.64 during trading on Thursday, reaching $1,093.08. 586,089 shares of the stock were exchanged, compared to its average volume of 916,639. McKesson has a 12 month low of $723.68 and a 12 month high of $1,121.50. The stock has a 50-day moving average price of $931.17 and a 200-day moving average price of $865.74. The firm has a market cap of $127.44 billion, a PE ratio of 29.13, a PEG ratio of 1.99 and a beta of 0.27.

Medtronic (MDT)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

NYSE:MDT traded down $1.03 during mid-day trading on Thursday, hitting $103.93. 5,737,783 shares of the stock were exchanged, compared to its average volume of 11,307,323. The stock has a market capitalization of $132.94 billion, a price-to-earnings ratio of 25.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.56. The firm’s 50-day simple moving average is $92.21 and its 200 day simple moving average is $88.39. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.54 and a current ratio of 2.07. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33.

Boston Scientific (BSX)

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

NYSE BSX traded down $1.51 on Thursday, reaching $44.31. The stock had a trading volume of 9,778,581 shares, compared to its average volume of 18,804,617. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.36 and a quick ratio of 0.74. The firm has a fifty day moving average of $44.47 and a two-hundred day moving average of $56.16. Boston Scientific has a 1-year low of $39.57 and a 1-year high of $105.65. The company has a market cap of $64.22 billion, a P/E ratio of 18.78, a price-to-earnings-growth ratio of 1.27 and a beta of 0.60.